The clinical correlation between CHIP and CVD was even higher for mutations in JAK2 than TET2. JAK2 V617F is the main driver mutation in patients with myeloproliferative neoplasm (MPN) who frequently suffer from thromboembolic complications [8,39]. Here, JAK2 is linked to myeloproliferative neoplasm.